Toyota|$17.22 (¥2,777)-0.61%▼ (in JPY terms)
Sony|$19.47 (¥3,140)-3.38%▼ (in JPY terms)
SoftBank|$44.09 (¥7,111)-1.08%▼ (in JPY terms)
MUFG|$20.32 (¥3,278)-2.85%▼ (in JPY terms)
Keyence|$481.77 (¥77,700)+0.23%▲ (in JPY terms)
Nintendo|$43.87 (¥7,076)-1.26%▼ (in JPY terms)
NTT|$0.90 (¥144)-2.37%▼ (in JPY terms)
Takeda|$30.59 (¥4,934)-2.04%▼ (in JPY terms)
Tokyo Electron|$467.26 (¥75,360)-0.95%▼ (in JPY terms)
Recruit|$67.37 (¥10,865)-2.69%▼ (in JPY terms)
ITOCHU|$11.46 (¥1,848)-1.26%▼ (in JPY terms)
Honda|$8.76 (¥1,413)-0.11%▼ (in JPY terms)
Shin-Etsu|$45.32 (¥7,310)-2.00%▼ (in JPY terms)
Tokio Marine|$44.61 (¥7,194)-1.77%▼ (in JPY terms)
Fast Retailing|$515.25 (¥83,100)-1.19%▼ (in JPY terms)
Toyota|$17.22 (¥2,777)-0.61%▼ (in JPY terms)
Sony|$19.47 (¥3,140)-3.38%▼ (in JPY terms)
SoftBank|$44.09 (¥7,111)-1.08%▼ (in JPY terms)
MUFG|$20.32 (¥3,278)-2.85%▼ (in JPY terms)
Keyence|$481.77 (¥77,700)+0.23%▲ (in JPY terms)
Nintendo|$43.87 (¥7,076)-1.26%▼ (in JPY terms)
NTT|$0.90 (¥144)-2.37%▼ (in JPY terms)
Takeda|$30.59 (¥4,934)-2.04%▼ (in JPY terms)
Tokyo Electron|$467.26 (¥75,360)-0.95%▼ (in JPY terms)
Recruit|$67.37 (¥10,865)-2.69%▼ (in JPY terms)
ITOCHU|$11.46 (¥1,848)-1.26%▼ (in JPY terms)
Honda|$8.76 (¥1,413)-0.11%▼ (in JPY terms)
Shin-Etsu|$45.32 (¥7,310)-2.00%▼ (in JPY terms)
Tokio Marine|$44.61 (¥7,194)-1.77%▼ (in JPY terms)
Fast Retailing|$515.25 (¥83,100)-1.19%▼ (in JPY terms)

Otsuka Holdings Co.,Ltd. (4578)

TSE 4578 · Pharmaceuticals

Otsuka Holdings Co.,Ltd.

大塚ホールディングス株式会社
$65.20 (¥10,515)
+285.0 (+2.79%)in JPY terms
Delayed quote · Yahoo Finance
🏢 Industry: Pharmaceuticals
🌐 ISIN: JP3188220002
📊 TSE: 4578
Company Overview

Otsuka Holdings is a diversified Japanese healthcare group with major businesses in pharmaceuticals, nutraceuticals, and consumer products. The company is best known internationally for its psychiatric and neurological medicines, as well as for the Pocari Sweat sports drink brand, which has achieved significant market penetration across Asia.

For international investors, Otsuka Holdings presents a distinctive combination of branded pharmaceuticals and consumer health products, providing a degree of earnings diversification uncommon among pure-play pharmaceutical companies. The group's psychiatric medicine portfolio, including treatments for schizophrenia and bipolar disorder, generates revenues across major global markets, while its consumer nutraceutical and beverage businesses contribute stable cash flows primarily across the Asia-Pacific region.

Recent Press Releases
2026-06-162026-06-15 Otsuka Holdings Co.,Ltd. “Regarding the completion of the acquisition of Transcend Therapeutics.”2026-06-122026-06-11 Otsuka Holdings Co.,Ltd. “58 years after its launch, Bon Curry's familiar taste is being passed on to the next generation. Otsuka Foods' Lake Biwa Research Institute has developed a taste and recipe prediction AI system called "Oishisa LENS" and has begun using it for technology transfer and product design.”2026-06-112026-06-10 Otsuka Holdings Co.,Ltd. “Otsuka Chemical and Gutenberg are collaborating with three student groups participating in the NHK Student Robot Contest using 3D printing technology.”2026-06-062026-06-05 Otsuka Holdings Co.,Ltd. “VOYXACT (sibeprenelimab), a treatment for IgA nephropathy, presents favorable eGFR data from a Phase 3 trial – reporting 12 months of maintained renal function at the European Society of Nephrology.”2026-06-062026-06-05 Otsuka Holdings Co.,Ltd. “The National Institute for Environmental Studies and other organizations have established the "Heatstroke Prevention Industry-Government-Academia Collaboration Consortium" to bring together scientific and practical knowledge to reduce the risk of heatstroke caused by climate change.”2026-05-302026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action, was presented at the American Society of Clinical Psychopharmacology (ASCP) annual meeting with post-hoc analysis results from a Phase 3 trial demonstrating improvements in executive function and emotional regulation in adults with ADHD.”2026-05-192026-05-18 Otsuka Holdings Co.,Ltd. “FACEDUO launches new program "Heatstroke Prevention VR" to allow users to experience the signs of heatstroke and take action to prevent it from occurring or becoming severe in the elderly.”2026-05-152026-05-14 Otsuka Holdings Co.,Ltd. “The US FDA has approved INQOVI and venetoclax combination therapy as the first oral-only combination therapy for patients with acute myeloid leukemia who are not suitable for intensive induction therapy.”2026-05-012026-04-30 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical has released a collection of educational materials and resources for teachers and staff to support health education in schools. Electronic health materials on topics such as heatstroke prevention and nutrition education are available free of charge.”2026-04-292026-04-28 Otsuka Holdings Co.,Ltd. “Taiho Oncology, Taiho Pharmaceutical, and Araris Inc. have initiated a Phase I clinical trial of the antibody-drug conjugate ARC-02.”
Key Data
52W High
$73.85 (¥11,910)
52W Low
$40.37 (¥6,511)
TSE Code
4578
ISIN
JP3188220002